Enhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm Injection

May 17, 2026 updated by: Hasnaa Osama, Beni-Suef University

Advances in Polycystic Ovarian Syndrome PCOS Management for Enhancing the Outcome of Intracytoplasmic Sperm Injection

The goal of this clinical trial is to evaluate and compare the effectiveness of combined Myoinositol and Metformin therapy versus a combination of Pioglitazone and Metformin, and Metformin alone in infertile women with Polycystic Ovary Syndrome (PCOS) undergoing Intracytoplasmic Sperm Injection (ICSI). The main questions it aims to answer are:

  • Which is more suitable clinical treatment schemes for PCOS women undergoing Intracytoplasmic Sperm Injection.
  • Researchers will compare metformin monotherapy as the control group to the combination of metformin and Myoinositol, or Metformin combination with Pioglitazone to see which is more effective treatment approach in PCOS women undergoing ICSI.

Participants will:

  • Take metformin, metformin and Myoinositol or Metformin and Pioglitazone every day for one month.
  • At 1-month post-drug therapy: Initial assessment should be conducted to evaluate the patient's response to the treatment, particularly focusing on ovarian function and any associated changes in reproductive parameters.

The percentage of oocytes reaching the second meiotic division will be evaluated, indicating the readiness for fertilization.

  • 18 hours post-ICSI: Fertilization rates will be determined by the proportion of oocytes that successfully undergo fertilization following ICSI, reflecting the immediate success of the procedure.
  • 3 days post-ICSI: The cleavage rate should be determined it is the percentage of fertilized oocytes that undergo cleavage within a specified timeframe will be assessed, providing insights into embryonic development.
  • At 14 days post-embryo transfer: determine chemical pregnancy rate.
  • At weeks 4-5 of gestation, the clinical pregnancy rate is confirmed by pulsation.
  • Ongoing pregnancy rate is confirmed at (12 weeks of gestation) is an important time point of a gestation.
  • Within 3 months post-ICSI: The abortion rate should be monitored the percentage of clinical pregnancies that result in spontaneous miscarriage prior to the 20-week gestation mark will be evaluated to assess the stability of pregnancies achieved.
  • Incidence of Side Effects: The frequency and severity of any adverse events related to the treatment will be monitored, contributing to the overall safety profile of the interventions.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Beni Suweif Governorate
      • Banī Suwayf, Beni Suweif Governorate, Egypt, 62521
        • Beni-suef university Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 20 and 45years who failed to conceive for >12 months.
  • BMI < 35kg/m2
  • Polycystic ovary syndrome women (PCOS)
  • bilateral patent tubes on hysterosalpingography/laparoscopy

Exclusion Criteria:

  • Male factor infertility
  • uncontrolled hypo/hyperthyroidism couples.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group I
Group I (n=50 PCOS patients) will be as the controlled group and receive metformin monotherapy.
Drug: Metformin monotherapy
metformin 850 mg tablets once daily for one month before ICSI
Experimental: Group II
Group II (n=50 PCOS patinets) will receive combination of Myoinositol at a dosage of 600 mg administered twice daily and metformin 850 mg tablets once daily for one month prior to undergoing Intracytoplasmic Sperm Injection (ICSI)
Combination product: Myoinositol and metformin
Myoinositol at a dosage of 600 mg administered twice daily and metformin 850 mg tablets once daily for one month prior to undergoing Intracytoplasmic Sperm Injection (ICSI)
Experimental: Group III
Group III (n=50 PCOS patients) will receive a combination of pioglitazone 15 mg and metformin 850 mg tablets once daily for one month before ICSI
Combination product: pioglitazone and metformin
A combination of pioglitazone 15 mg and metformin 850 mg tablets once daily for one month before ICSI.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fertilization rate
Time Frame: 3 months of follow-up
the percentage of fertilized oocytes the specified timeframe will be assessed.
3 months of follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Abortion rate
Time Frame: 3 months
The percentage of clinical pregnancies that result in spontaneous miscarriage prior to the 20-week gestation mark will be evaluated to assess the stability of pregnancies achieved.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beni-Suef University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 17, 2026

Primary Completion (Estimated)

December 3, 2026

Study Completion (Estimated)

March 3, 2027

Study Registration Dates

First Submitted

May 17, 2026

First Submitted That Met QC Criteria

May 17, 2026

First Posted (Actual)

May 22, 2026

Study Record Updates

Last Update Posted (Actual)

May 22, 2026

Last Update Submitted That Met QC Criteria

May 17, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FMBSUREC/01082026/Mohamed

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Polycystic Ovarian Syndrome (PCOS)

Clinical Trials on Metformin monotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe